Bairu Menghisteab 4
4 · BRAINSTORM CELL THERAPEUTICS INC. · Filed May 20, 2026
Research Summary
AI-generated summary of this filing
Brainstorm (BCLI) Director Bairu Menghisteab Receives Option Award
What Happened Bairu Menghisteab, a director of BrainStorm Cell Therapeutics, received an award of options to acquire 150,000 shares on February 26, 2026. The options have a reported acquisition price of $0.70 per share (150,000 × $0.70 = $105,000) and are reported as a derivative award (transaction code A).
Key Details
- Transaction date: 2026-02-26 (Form 4 filed 2026-05-20; filing was late)
- Award: Options for 150,000 shares at $0.70 per share (reported $105,000)
- Vesting: 50% vested on grant; remaining 50% vests six months after grant, contingent on continued service (see footnotes F1–F2)
- Plan: Granted under the Issuer's 2014 Stock Incentive Plan (footnote F1)
- Shares owned after transaction: Not specified in the filing
- Transaction type/code: Derivative grant / Code A (award/grant)
Context This was an option grant (an award), not a cash purchase or sale. Exercising the options in the future would require payment of the $0.70 exercise price per share and completion of the vesting conditions. The late filing delays public disclosure of the grant but does not, by itself, indicate the insider’s intent.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-02-26$0.70/sh+150,000$105,000→ 150,000 totalExercise: $0.70Exp: 2036-02-26→ Common Stock (150,000 underlying)
Footnotes (2)
- [F1]Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
- [F2]The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.